Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Teva
Israel - Petach Tikva
DIAZOXIDE (diazoxide) by Teva is clinical pharmacology diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. Approved for hypoglycemia due to hyperinsulinism associated with the following conditions: adults: inoperable islet cell adenoma, carcinoma, extrapancreatic malignancy. First approved in 2019.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. The hyperglycemic effect of diazoxide begins within an hour and generally lasts no more than eight hours in…
Worked on DIAZOXIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
Diazoxide Choline in Hypertriglyceridemia
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo